Filing Flows › Teleflex (TFX) › Q3 2026 › vs Q3 2025
Teleflex (TFX) Q3 2026 vs Q3 2025 (year over year)
Teleflex's revenue rose $837K (+0.1%) from $567M in Q3 2025 to $568M in Q3 2026. The biggest changes: Vascular +$10.9M (+5%); Interventional −$5.7M (-3%); Surgical +$4.6M (+4%). Gross margin 65.0% against 51.5% (+13.4 pts).
Teleflex, Q3 2026: revenue $568M (+0.1% year over year), operating margin 18.6%, net earnings $927M, operating cash flow $96.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 65.0% | 51.5% | +13.4 pts |
| Operating margin | 18.6% | -11.0% | +29.6 pts |
| Net margin | 163.3% | -72.1% | +235.5 pts |
| Free cash flow margin | 13.1% | 0.0% | +13.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Vascular | $243M | $233M | $10.9M | +5% |
| Interventional | $210M | $216M | −$5.7M | -3% |
| Surgical | $114M | $109M | $4.6M | +4% |
| Revenue | $568M | $567M | $837K | +0.1% |
| Gross profit | $369M | $292M | $76.7M | +26% |
| Cost of revenue | $199M | $275M | −$75.9M | -28% |
| Other income, net | $851M | −$380M | $1.2B | — |
| Operating profit | $105M | −$62.4M | $168M | — |
| Operating expenses | $263M | $354M | −$91.1M | -26% |
| Pre-tax earnings | $956M | −$443M | $1.4B | — |
| Research & development | $43.0M | $44.3M | −$1.3M | -3% |
| SG&A | $221M | $207M | $13.3M | +6% |
| Net earnings | $927M | −$409M | $1.3B | — |
| Income tax | $28.8M | −$34.0M | $62.8M | — |
| Depreciation & amortization | $51.6M | $48.7M | $2.9M | +6% |
| Share-based compensation | $6.3M | $6.7M | −$449K | -7% |
| Working capital & other | $889M | −$373M | $1.3B | — |
| Operating cash flow | $96.3M | $19.6M | $76.7M | +392% |
| Free cash flow (OCF − capex) | $74.7M | $69K | $74.6M | 1,082× |
| Capital expenditures | $21.6M | $19.5M | $2.1M | +11% |
Questions
How much did Teleflex's revenue grow year over year in Q3 2026?
Teleflex's revenue rose $837K (+0.1%) from $567M in Q3 2025 to $568M in Q3 2026.
What drove Teleflex's revenue change in Q3 2026?
Vascular +$10.9M (+5%); Interventional −$5.7M (-3%); Surgical +$4.6M (+4%).